Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Myriad Genetics Inc (NQ: MYGN )

15.15 -0.15 (-0.95%)
Streaming Delayed Price Updated: 3:57 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 486,017
Open 15.33
Bid (Size) 15.15 (9)
Ask (Size) 15.16 (8)
Prev. Close 15.30
Today's Range 14.94 - 15.61
52wk Range 14.72 - 29.30
Shares Outstanding 90,900,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
Agreement will expand worldwide access and better position Myriad’s GIS as a potential companion diagnostic across multiple potential tumor types 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
From Myriad Genetics, Inc.
Via GlobeNewswire

Performance

YTD
-20.24%
-20.24%
1 Month
-32.76%
-32.76%
3 Month
-45.74%
-45.74%
6 Month
-36.83%
-36.83%
1 Year
-13.30%
-13.30%

More News

Read More
Where Myriad Genetics Stands With Analysts
Via Benzinga
Analyst Expectations For Myriad Genetics's Future
Via Benzinga
Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
From Myriad Genetics, Inc.
Via GlobeNewswire
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results
Via Benzinga
Exposures Fossil Fuels
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results
Via Benzinga
Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
G-III Apparel Posts Upbeat Results, Joins NIO, Yext, Shoe Carnival And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Myriad Genetics to Host Investor Event on October 9, 2024
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
Thermo Fisher Scientific Stock Sees RS Rating Jump To 81
Via Investor's Business Daily
MYGN Stock Earnings: Myriad Genetics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.